Press release from Companies
Publicerat: 2020-01-20 12:23:03
ODI Pharma AB"s ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed and the Company will through the issue receive SEK 25 million before issue costs and around 1,360 new shareholders. For the listing date to take place on the communicated date, the new share issue has been partially registered at the Swedish Companies Registration Office. 2,579,114 shares out of the total of 2,720,000 shares that were subscribed in the new share issue, have now been registered and will be made available for trading on the 23rd of January 2020. The new share issue"s second and also last registration is set to take place within this week.
Number of shares and share capital Due to the fact that some payments were missing on the last day of payment, the new share issue has been partially registered. In the first registration, 2,579,114 shares have been registered with the Swedish Companies Registration Office. The Company"s total number of shares thus currently amount to 15,079,114 shares and the share capital amounts to SEK 603,164.56. The remaining part of the new share issue is intended to be registered at the Swedish Companies Registration Office within this week. When the entire new share issue has been registered at the Swedish Companies Registration Office, ODI Pharma"s total number of shares will amount to 15,220,000 and the share capital of the Company will amount to SEK 608,800.00. Listing on Spotlight Stock Market The first day of trading in ODI Pharma"s shares on Spotlight Stock Market will be the 23rd of January 2020. The short name for the share is "ODI" and the ISIN-code is SE0013409760. Financial and legal advisor Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in the new share issue and the listing on Spotlight Stock Market. For more information on ODI Pharma, please contact: Derek Simmross, CEO, ODI Pharma AB E-mail: info@odipharma.com For more information regarding the new share issue and listing, please contact: Sedermera Fondkommission Phone: +46 40 615 14 10 E-mail: info@sedermera.se ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.
